Literature DB >> 33136300

Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care: A joint position statement from the Heart Failure Association (HFA), European Heart Rhythm Association (EHRA), and European Association of Cardiovascular Imaging (EACVI) of the European Society of Cardiology.

Wilfried Mullens1,2, Angelo Auricchio3, Pieter Martens1,2, Klaus Witte4, Martin R Cowie5, Victoria Delgado6, Kenneth Dickstein7, Cecilia Linde8, Kevin Vernooy9,10, Francisco Leyva11, Johann Bauersachs12, Carsten W Israel13, Lars H Lund14, Erwan Donal15, Giuseppe Boriani16, Tiny Jaarsma17,18, Antonio Berruezo19, Vassil Traykov20, Zaheer Yousef21, Zbigniew Kalarus22, Jens Cosedis Nielsen23, Jan Steffel24, Panos Vardas25, Andrew Coats26, Petar Seferovic27, Thor Edvardsen28, Hein Heidbuchel29, Frank Ruschitzka30, Christophe Leclercq15.   

Abstract

Cardiac resynchronization therapy (CRT) is one of the most effective therapies for heart failure with reduced ejection fraction and leads to improved quality of life, reductions in heart failure hospitalization rates and all-cause mortality. Nevertheless, up to two-thirds of eligible patients are not referred for CRT. Furthermore, post-implantation follow-up is often fragmented and suboptimal, hampering the potential maximal treatment effect. This joint position statement from three European Society of Cardiology Associations, Heart Failure Association (HFA), European Heart Rhythm Association (EHRA) and European Association of Cardiovascular Imaging (EACVI), focuses on optimized implementation of CRT. We offer theoretical and practical strategies to achieve more comprehensive CRT referral and post-procedural care by focusing on four actionable domains: (i) overcoming CRT under-utilization, (ii) better understanding of pre-implant characteristics, (iii) abandoning the term 'non-response' and replacing this by the concept of disease modification, and (iv) implementing a dedicated post-implant CRT care pathway. © the Author(s) 2020. This article has been co-published with permission in European Journal of Heart Failure (published by John Wiley & Sons Ltd on behalf of European Society of Cardiology) and EP Europace.

Entities:  

Keywords:  Cardiac resynchronization therapy; Care pathways; Disease management; Disease modification; Heart failure; Implementation; Outcome; Response; Utilization

Mesh:

Year:  2020        PMID: 33136300     DOI: 10.1002/ejhf.2046

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  23 in total

1.  [Patient with a defibrillator for cardiac resynchronization therapy (CRT-D) and progressive symptoms of heart failure].

Authors:  Ralph Bosch
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2021-11-08

2.  Dapagliflozin Versus Sacubitril-Valsartan to Improve Outcomes of Patients with Reduced Ejection Fraction and Diabetes Mellitus.

Authors:  Ariel Hammerman; Joseph Azuri; Enis Aboalhasan; Ronen Arbel
Journal:  Am J Cardiovasc Drugs       Date:  2021-10-21       Impact factor: 3.571

3.  Regional Left Ventricular Fiber Stress Analysis for Cardiac Resynchronization Therapy Response.

Authors:  Mohammad Albatat; Henrik Nicolay Finsberg; Hermenegild Arevalo; Joakim Sundnes; Jacob Bergsland; Ilangko Balasingham; Hans Henrik Odland
Journal:  Ann Biomed Eng       Date:  2022-07-27       Impact factor: 4.219

4.  Acute Hemodynamic Effects of Simultaneous and Sequential Multi-Point Pacing in Heart Failure Patients With an Expected Higher Rate of Sub-response to Cardiac Resynchronization Therapy: Results of Multicenter SYNSEQ Study.

Authors:  Maciej Sterliński; Joanna Zakrzewska-Koperska; Aleksander Maciąg; Adam Sokal; Joaquin Osca-Asensi; Lingwei Wang; Vasiliki Spyropoulou; Baerbel Maus; Francesca Lemme; Osita Okafor; Berthold Stegemann; Richard Cornelussen; Francisco Leyva
Journal:  Front Cardiovasc Med       Date:  2022-05-12

5.  The year in cardiovascular medicine 2021: heart failure and cardiomyopathies.

Authors:  Johann Bauersachs; Rudolf A de Boer; JoAnn Lindenfeld; Biykem Bozkurt
Journal:  Eur Heart J       Date:  2022-02-03       Impact factor: 35.855

6.  Five-year mortality of heart failure with preserved, mildly reduced, and reduced ejection fraction in a 4880 Chinese cohort.

Authors:  Shiqun Chen; Zhidong Huang; Yan Liang; Xiaoli Zhao; Xiemuxikaimaier Aobuliksimu; Bo Wang; Yibo He; Yu Kang; Haozhang Huang; Qiang Li; Younan Yao; Xiaozhao Lu; Xiaoxian Qian; Xujing Xie; Jin Liu; Yong Liu
Journal:  ESC Heart Fail       Date:  2022-04-18

Review 7.  Electrical management of heart failure: from pathophysiology to treatment.

Authors:  Frits W Prinzen; Angelo Auricchio; Wilfried Mullens; Cecilia Linde; Jose F Huizar
Journal:  Eur Heart J       Date:  2022-05-21       Impact factor: 35.855

8.  December 2020 at a glance: focus on COVID-19, comorbidities and palliative care.

Authors:  Daniela Tomasoni; Marianna Adamo; Marco Metra
Journal:  Eur J Heart Fail       Date:  2020-12       Impact factor: 15.534

Review 9.  Remote monitoring and telemedicine in heart failure: implementation and benefits.

Authors:  Jacopo Francesco Imberti; Alberto Tosetti; Davide Antonio Mei; Anna Maisano; Giuseppe Boriani
Journal:  Curr Cardiol Rep       Date:  2021-05-07       Impact factor: 2.931

10.  Remote Hemodynamic-Guided Therapy of Patients With Recurrent Heart Failure Following Cardiac Resynchronization Therapy.

Authors:  Niraj Varma; Robert C Bourge; Lynne Warner Stevenson; Maria Rosa Costanzo; David Shavelle; Philip B Adamson; Greg Ginn; John Henderson; William T Abraham
Journal:  J Am Heart Assoc       Date:  2021-02-25       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.